Back
to home » Treatment News » Top Stories
 January 30, 2009
|
Once-Daily Better Than Twice-Daily HIV Treatment
Once-daily antiretroviral (ARV) regimens are better than twice-daily regimens in both adherence and viral suppression for people new to treatment, according to a study published in the February 15 issue of Clinical Infectious Diseases and reported by aidsmap.com.
|
|
|
January 29, 2009
|
Non-AIDS Cancers on the Rise
The percentage of HIV-positive people diagnosed with non-AIDS-related cancers, particularly hepatitis-related cancers, increased between 2000 and 2005, according to a study published online January 28 in the journal Clinical Infectious Diseases.
|
|
|
January 28, 2009
|
New Heat-Stable Norvir Tablet Sent to FDA for Approval
Paperwork for a new heat-stable tablet formulation of Norvir (ritonavir) has been submitted to the U.S. Food and Drug Administration (FDA) for approval, according to an announcement by the drug’s maker, Abbott Laboratories. Unlike the current Norvir capsules, the new tablet will not have to be refrigerated.
|
|
|
January 27, 2009
|
HIV Treatment Boosts Lung Cancer Survival in People With HIV
HIV-positive people with lung cancer have increased survival if they are receiving antiretroviral (ARV) treatment along with cancer treatment, according to a study published online in the journal Lung Cancer and reported by aidsmap.com. This is one of the first studies to find a direct impact of ARV treatment on surviving a non-AIDS-related cancer.
|
|
|
January 26, 2009
|
Earlier HIV Treatment Protects Against Hep C Liver Damage
Starting antiretroviral (ARV) HIV treatment sooner may protect people infected with both HIV and hepatitis C virus (HCV) against liver damage, according to the authors of a study published in the February 2009 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
January 23, 2009
|
No Evidence of Superinfection Between Long-Term Partners
Becoming infected with a second strain of HIV after a person is already infected—called superinfection—may not be a risk for couples who are both HIV positive and don’t use condoms, according to a study published in the October 2008 issue of PLoS Pathogens and reported by aidsmap.com.
|
|
|
January 22, 2009
|
Myriad Acquires Rights to Develop Bevirimat
Salt Lake City-based Myriad Pharmaceuticals has purchased the rights to develop and eventually sell bevirimat, a promising HIV maturation inhibitor currently in Phase II studies discovered by Panacos Pharmaceuticals, based in Watertown, Massachusetts.
|
|
|
| January 21, 2009
|
January 20, 2009
|
Project Inform Founder Martin Delaney Honored for AIDS Work
The National Institute of Allergy and Infectious Diseases (NIAID) presented AIDS activist Martin Delaney, founder and longtime director of HIV advocacy and education organization Project Inform, with the NIAID Director’s Special Recognition Award for his contributions to the fight against AIDS, according to the institute’s website.
|
|
|
January 16, 2009
|
Prezista’s Potency Enhanced by 2 HIV Mutations
Researchers have found several new HIV mutations that decrease the effectiveness of Prezista (darunavir) and two that actually increase its effectiveness, according to a study published online January 15 in the Journal of Antimicrobial Chemotherapy.
|
|
|
January 15, 2009
|
Poor Viral Control With Once-Daily Viramune, Viread and Epivir
People on a once-a-day regimen of Viramune (nevirapine), Viread (tenofovir) and Epivir (lamivudine) had a very high risk of early virologic treatment failure, according to a study published in the February issue of the Journal of Antimicrobial Chemotherapy.
|
|
|
| January 14, 2009
|
January 13, 2009
|
Gilead Developing New Four-in-One HIV Drug
A four-in-one antiretroviral pill is being developed by Gilead Sciences and, according to a report by Bloomberg News, is expected to enter a clinical trial by this summer.
|
|
|
January 12, 2009
|
Premature Aging of CD4 Cells Linked to Faster Disease Progression
While they may not develop wrinkles or liver spots, CD4 cells can show signs of premature aging. This can lead to faster disease progression in HIV-positive people, conclude the authors of a study published in the January 7 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
January 09, 2009
|
IL-2 Doesn’t Increase Lymphoma Risk
A French study has concluded that Proleukin (Interleukin-2, IL-2) does not appear to increase the likelihood of developing either Hodgkin’s disease (HD) or non-Hodgkin’s lymphoma (NHL), debunking some concerns that this possible immune-based therapy may be associated with a greater risk of these life-threatening cancers. The encouraging data were published online January 7 in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
January 08, 2009
|
Missed Doctors Appointments Bad for Survival
Missed visits to the doctor in the first year of HIV care may double the risk of death, according to a study published in the January 15 issue of Clinical Infectious Diseases.
|
|
|
| January 07, 2009
|
January 06, 2009
|
Not Enough Antibodies to Protect Against Superinfection
Most people’s immune response to HIV isn’t strong enough to protect them from being infected with a second strain of the virus, according to a study published in the December 2008 issue of the Journal of Virology and reported by ScienceDaily.
|
|
|
January 05, 2009
|
Up Kaletra Dose During Late Pregnancy
HIV-positive pregnant women should take a higher-than-normal dose of Kaletra (lopinavir/ritonavir) during the three months leading up to delivery, according to a study published online in the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
|
|
